Back to All Events

Partnerships Between Private and Public Institutions

Partnerships Between Private and Public Institutions

September 14, 2015


Location: Cambridge, MA

Venue: Hyatt Regency Cambridge, MA

Breaking Down Barriers: Partnerships Between Private and Public Institutions to Accelerate Medical Research

Speaker: Adrienne Tymiak, Bristol-Myers Squibb

The Power of Precompetitive Cooperation:  The International Consortium on Innovation and Quality in Pharmaceutical Development (IQ) and The Allotrope Foundation (AF)

The challenges to the Biopharmaceutical industry have never been greater as it pursues new and improved therapeutic treatments for refractory and complex medical conditions.  By some accounts, the industry invests over $50B annually to fund both proprietary research as well as nonproprietary activities that are needed to bring a drug to market.  Industry-wide, such nonproprietary activities are conducted independently in each company and contribute to redundancy or “reinventing the wheel”.  In addition, there are challenges in the precompetitive space of biopharmaceutical research that are too large to be tackled by any one company alone.  Precompetitive cooperation is a way to increase overall productivity by working collectively, avoiding redundant work and leveraging a critical mass of effort to address larger challenges and facilitate scientific interactions with health authorities.  This presentation describes two examples of organized cooperation in the Biopharmaceutical industry and their accomplishments to date.  The IQ consortium, with its 38 member companies and hundreds of individual participants, has contributed to the advancement of pharmaceutical sciences through numerous workshops, webinars, publications and conferences.  In 2012, the IQ consortium launched the Allotrope Foundation as a separate initiative to develop an analytical data management framework and software toolkit to streamline workflows.

Speaker biography:

Adrienne Tymiak, PhD, is Executive Director of Bioanalytical and Discovery Analytical Sciences at Bristol-Myers Squibb (BMS).  The scientific focus of her department is characterization and quantification of small molecules, biologics, impurities, metabolites, target proteins and translational biomarkers.  As an analytical leader at BMS, she contributed to the discovery of over a dozen novel bioactive natural products, established the open access analytical infrastructure for medicinal chemists, built capabilities and facilities for chiral analysis, protein characterization, preclinical and clinical (regulated) bioanalysis, imaging and metabolomics and implemented innovative technologies, informatics solutions and global collaborations with academic and industrial partners.   Adrienne is a board member for the International Consortium for Innovation and Quality in Pharmaceutical Development and the Allotrope Foundation.   Over her career, Adrienne has been an invited speaker at national and international conferences with over 60 publications, book chapters and patents and more than 80 external presentations and posters.  Adrienne obtained an A.B. in Biochemistry at Cornell University, an M.S. in Chemical Oceanography at Florida State University and a PhD in Organic Chemistry at the University of Illinois, Champaign-Urbana.